In an Australian first, a vaccine for respiratory syncytial virus or RSV has been approved by the therapeutic goods administration and will soon be available for those aged 60 and above. The vaccine is a protein-based immunisation to help prevent lower respiratory tract disease caused by RSV, which can be fatal.
